Servier, a global pharmaceutical company, completed the acquisition of the oncology business of Agios Pharmaceuticals, a public American pharmaceutical company, for $2bn. The deal value includes upfront payment of $1.8bn and a potential $200m in regulatory milestone, plus royalties. "The strategic acquisition of Agios' oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognized player in oncology and further supports our commitment to provide innovative treatments to cancer patients with unmet medical needs. It is a key step for the Servier Group as it will significantly strengthen our position in the U.S. and reinforce our R&D capabilities in oncology," Olivier Laureau, Servier President.